Remove DEA Remove Extraction Remove Legalization Remove Research and Development
article thumbnail

DEA Seeks to Increase Quota of Cannabis and Psilocybin for Research Purposes

SpeedWeed

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. “DEA

DEA 52
article thumbnail

F the Treaties: Rescheduling and “Marijuana-Specific Controls”

Canna Law Blog

The Drug Enforcement Administration (DEA) published its Notice of Proposed Rulemaking (“NOPR”) last week to much fanfare. The NOPR would reschedule marijuana, “marijuana extract” and “naturally derived delta-9 tetrahydrocannabinols” from schedule I to schedule III of the Controlled Substances Act (CSA). But that’s not all.

DEA 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

FDA Guidance on Cannabis Research: A Glimpse of What’s To Come for CBD Products?

Canna Law Blog

On Tuesday, July 21, the Food and Drug Administration (“FDA”) released draft guidance for clinical research related to the development and manufacturing of cannabis-based drugs, which gained particular interest following the legalization of hemp in December 2018. percent limit.

CBD 92
article thumbnail

Kelley Drye: CBD and Hemp Legal and Regulatory Roundup – July 2021 #1

Cannabis Law Report

Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news: CBD. The Congressional Research Service (CRS) released a report which says there are “three leading markets for hemp, each based on the part of the plant used: fiber, seed/grain, and flower.” Published To JD Supra. Marijuana Moment. Marijuana Moment.

Hemp 105
article thumbnail

Denver Cannabis Company to Expand Alzheimer’s Research

SpeedWeed

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

article thumbnail

Clever Leaves and Biopharmaceutical Research Company to Partner for Landmark Cannabis Research Study in Collaboration with the University of California, Davis

Cannabis Law Report

The initiative is part of Project Change Lives; Clever Leaves’ $25M product pledge to aid cannabis research in the U.S. The collaboration represents the Company’s first funded study with a research institution in the United States. organization to help advance scientific research into the potential medical benefits of cannabinoids.